Sarepta Therapeutics
SRPT
#1426
Rank
$12.44 B
Marketcap
$130.47
Share price
0.20%
Change (1 day)
21.20%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

P/E ratio for Sarepta Therapeutics (SRPT)

P/E ratio as of October 2024 (TTM): -16.5

According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.5006. At the end of 2022 the company had a P/E ratio of -16.1.

P/E ratio history for Sarepta Therapeutics from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-16.1-7.71%
2021-17.5-27.49%
2020-24.180.9%
2019-13.3-33.79%
2018-20.1-72.14%
2017-72.31338.35%
2016-5.02-32.42%
2015-7.4374.15%
2014-4.27-28.96%
2013-6.0119.25%
2012-5.04-92.16%
2011-64.3809.7%
2010-7.0725.84%
2009-5.62189.28%
2008-1.94-25.66%
2007-2.61-55.66%
2006-5.89-36.84%
2005-9.32173.78%
2004-3.41-59%
2003-8.3189.38%
2002-4.39-52.96%
2001-9.32

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
20.0-221.17%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.37-91.67%๐Ÿ‡บ๐Ÿ‡ธ USA
-14.2-14.16%๐Ÿ‡บ๐Ÿ‡ธ USA
-6.48-60.73%๐Ÿ‡บ๐Ÿ‡ธ USA
-69.0 318.42%๐Ÿ‡บ๐Ÿ‡ธ USA
-4.78-71.05%๐Ÿ‡บ๐Ÿ‡ธ USA
-13.5-18.34%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.